联环药业上涨6.5%，报20.16元/股

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. experienced a stock price increase of 6.5% on August 4, reaching 20.16 yuan per share, with a trading volume of 904 million yuan and a turnover rate of 16.63%, resulting in a total market capitalization of 5.755 billion yuan [1] Company Overview - Jiangsu Lianhuan Pharmaceutical is located in Yangzhou, Jiangsu Province, and is recognized as a national high-tech enterprise. The company integrates research and development, production, and sales, specializing in various pharmaceutical forms including tablets, hard capsules (including hormone types), suppositories (hormone types), and granules, with an annual production capacity of 5 billion pieces [1] - The company's main product lines include urological, antihistamine, cardiovascular, steroid hormone, and antibiotic categories, with over 100 varieties and specifications. Key products include the first-class new drug Aipulete, the second-class new drug Ebastine, and core products like Felodipine. The company boasts a high-end R&D team of nearly 200 people and multiple R&D platforms [1] Financial Performance - For the first quarter of 2025, Jiangsu Lianhuan Pharmaceutical reported an operating income of 628 million yuan, representing a year-on-year growth of 18.78%. However, the net profit attributable to shareholders was 23.0596 million yuan, reflecting a year-on-year decrease of 29.15% [1] - As of March 31, the number of shareholders for Lianhuan Pharmaceutical was 30,300, with an average of 9,416 circulating shares per person [1]